Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

vandetanib

View Patient Information
An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Caprelsa
Zactima
Foreign brand name:Lucivand
Code name:AZD6474
ZD-6474
ZD6474
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search